Equibles does not estimate personal net worth.
Get an email with a short summary when Pulse Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get PLSE alertsPaul A. LaViolette is recorded as CEO at Pulse Biosciences, Inc. (PLSE) since January 9, 2025 and Chairman and Board Member at Pulse Biosciences, Inc. (PLSE) since August 9, 2024. The newest filing on record that lists Paul A. LaViolette as CEO and Board Member at Pulse Biosciences, Inc. (PLSE) is dated May 11, 2026. Pulse Biosciences, Inc. reported in an 8-K filed January 13, 2025 that Paul A. LaViolette was appointed Chief Executive Officer and President, effective January 9, 2025. Pulse Biosciences, Inc. reported in an 8-K filed August 12, 2024 that Paul A. LaViolette was appointed Chairman of the Board's newly created Strategic Advisory Committee, effective August 9, 2024. Pulse Biosciences, Inc. reported in an 8-K filed August 12, 2024 that Paul A. LaViolette was appointed Co-Chairman of the Board, effective August 9, 2024. Equibles holds 4 filed executive changes naming Paul A. LaViolette; each is listed under recent activity with its source filing. The proxy statement of Pulse Biosciences, Inc. reports total compensation of $7,427,899 for Paul A. LaViolette in fiscal 2025, including a base salary of $708,523. Disclosed compensation is on record for 4 fiscal years. Paul A. LaViolette has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Pulse Biosciences, Inc. on June 10, 2026. Pulse Biosciences, Inc. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Pulse Biosciences, Inc. includes Burke T. Barrett (CEO and Board Member), Kevin Danahy (CEO), Paul LaViolette (CEO and Board Member) and 7 others.
“The Board of Directors of Pulse Biosciences, Inc. (the "Company") has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer and President of the Company, effective as of January 9, 2025 (the "Start Date"). In connection with his appointment, Mr. LaViolette will also serve as the Company's principal executive officer and principal financial officer.”
“appointed Mr. LaViolette to serve on the Board's Audit Committee and Corporate Governance and Nominating Committee and to serve as Chairman of the Board's newly created Strategic Advisory Committee.”
“I think it compares really favorably, to use your phrase, to the bevy of opportunities. If I think about what attracted me, it's not surprising, right, with what's going on in the field of PFA in the last couple of years that PFA, by definition, draws interest.”
“Today, I'm excited to share updates on the progress Pulse Biosciences has made in each of our 3 market development programs.”
2025-01-09–present
Last confirmed May 11, 2026
2024-08-09–present
2024-08-09–present
Last confirmed May 11, 2026
SEC 8-K
2024-08-09–present
Medical Instruments & Supplies · Healthcare
CEO, Chairman, Board Member
2024-08-09–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Pulse Biosciences, Inc. (PLSE) | Chief Executive Officer and Co-Chairman | $708,523 | $7,427,899 |
| 2024 | Pulse Biosciences, Inc. (PLSE) | Chief Executive Officer and Co-Chairman | — | — |
| 2023 | Pulse Biosciences, Inc. (PLSE) | Chief Executive Officer and Co-Chairman | — | — |
| 2022 | Pulse Biosciences, Inc. (PLSE) | Chief Executive Officer and Co-Chairman | — | — |
